Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 17/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.57 |
| ▸ | PDE4A | P27815 | 15/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836687 | 0.95 | PDE4D (0.62) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL6833314 | 0.95 | PDE4D (0.62) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL6833375 | 0.88 | KDM4E (0.57) | PDE4DPDE4BPDE4APDE4CKDM4E | |
| SCHEMBL5723285 | 0.87 | PDE4D (0.61) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL5798456 | 0.82 | PDE4D (0.63) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL3307253 | 0.82 | PDE4A (0.62) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL5723181 | 0.81 | PDE4A (0.64) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL5722882 | 0.81 | PDE4D (0.58) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL8269091 | 0.80 | PDE4D (0.60) | PDE4DPDE4BPDE4APDE4CGFER | |
| SCHEMBL6838082 | 0.79 | PDE4D (0.65) | PDE4DPDE4BPDE4APDE4CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-0943613-A1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1999-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | PDE4D 4870/4885PDE4B 4877/4885PDE4A 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.